Gastrointestinal Stromal Tumor Clinical Trial
Official title:
A Phase II Study of Adjuvant STI571 (Gleevec TM) Therapy in Patients Following Completely Resected High-risk Primary GastroIntestinal Stromal Tumor (GIST)
This phase II trial is studying how well imatinib mesylate works in treating patients with gastrointestinal stromal tumor that was completely removed during surgery. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth
Status | Completed |
Enrollment | 89 |
Est. completion date | |
Est. primary completion date | November 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 16 Years and older |
Eligibility |
Inclusion Criteria: - Patient must have an ECOG/Zubrod performance status of = 2 - Patient must have a diagnosis of high-risk primary GIST; NOTE: High risk is defined as tumor size = 10 cm in maximum dimension, or the presence of tumor rupture before or during surgery, intraperitoneal hemorrhage or multifocal (< 5) intraperitoneal tumors - Patient must have undergone complete gross resection (includes R0 [negative microscopic margins] and R1 [positive microscopic margins] resections) of a primary GIST within 70 days prior to registration - Patient must have a histologic diagnosis of GIST that is confirmed by central pathology review - Patient's tumor must stain positive for the Kit receptor tyrosine kinase on immunohistochemistry as determined by the central pathologist using the Dako (Dako Corp., Carpinteria, CA) anti-CD 117 antibody - Patient must have a chest x-ray completed within 28 days prior to registration - Patient must have a post-operative CT scan with IV and PO contrast or MRI with contrast (if allergic to CT contrast) of abdomen and pelvis within 28 days prior to registration - Creatinine = 1.5 times the institution ULN - WBC = 2,000/mm^3 - Platelet = 100,000/mm^3 - Total bilirubin = 1.5 times the institution ULN - AST and ALT = 2.5 times the institution ULN - Female of childbearing potential must have negative serum pregnancy test - Patient or the patient's legally acceptable representative must provide a signed and dated written informed consent prior to registration and any study related procedures - If patient is a cancer survivor, each of the following criteria must apply: - Patient has undergone potentially curative therapy for all prior malignancies, - No evidence of any prior malignancies for at least 5 years with no evidence of recurrence (except for effectively treated basal cell or squamous carcinoma of the skin, carcinoma in-situ of the cervix that has been effectively treated by surgery alone, or lobular carcinoma in-situ of the ipsilateral or contralateral breast treated by surgery alone) - Patient is deemed by their treating physician to be at low risk for recurrence from prior malignancies Exclusion Criteria: - Patient has received post-operative chemotherapy - Patient has received post-operative radiation therapy - Patient has received post-operative investigational treatment - Patient has received prior therapy with STI571 - Patient has had an active infection requiring antibiotics within 14 days prior to registration - Patient has objective evidence of residual disease on the post-operative CT scan or MRI of the abdomen or pelvis - Patient, if female and breastfeeding; NOTE: It is not known whether STI571 or its metabolites are excreted in human milk; however, in lactating female rats administered 100 mg/kg, a dose approximately equal to the maximum clinical dose of 800 mg/day based on body surface area, STI571 and/or its metabolites were extensively excreted in milk; it is estimated that approximately 1.5% of a maternal dose is excreted into milk, which is equivalent to a dose to the infant of 30% the maternal dose per unit body weight; because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, women should be advised against breastfeeding while taking STI571 - Patient has New York Heart Association class 3 or 4 cardiac disease - Patient is taking full dose warfarin; NOTE: The use of mini-dose warfarin (1 mg orally per day) for prevention of central line-associated deep venous thrombosis is permitted |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | American College of Surgeons Oncology Group | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determination whether patients with completely resected high-risk primary GIST who undergo adjuvant treatment with imatinib mesylate have prolonged survival compared to historical controls | Up to 5 years | No | |
Secondary | Prevalence of recurrence free survival | Marginal point and two-sided 95% (pointwise) confidence bands, based on Kaplan-Meier estimator will be produced. | 2 years | No |
Secondary | Prevalence of recurrence | Marginal point and two-sided 95% (pointwise) confidence bands, based on Kaplan-Meier estimator will be produced. | 5 years | No |
Secondary | Overall survival | Marginal point and two-sided 95% (pointwise) confidence bands, based on Kaplan-Meier estimator will be produced. | Up to 5 years | No |
Secondary | Toxicities, graded according to the National Cancer Institute Common Toxicity Criteria | Up to 10 years | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04933669 -
Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
|
Phase 2 | |
Completed |
NCT01769248 -
Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
|
N/A | |
Completed |
NCT01774162 -
EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration
|
N/A | |
Completed |
NCT01110668 -
Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
|
Phase 2 | |
Terminated |
NCT00091078 -
Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery
|
Phase 2 | |
Active, not recruiting |
NCT00265798 -
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
|
Phase 2 | |
Recruiting |
NCT04143048 -
A Study on Non-invasive Early Diagnosis of Gastrointestinal Stromal Tumors and Differentiation of Benign and Malignant Nodules
|
||
Recruiting |
NCT02931981 -
Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor
|
N/A | |
Not yet recruiting |
NCT02576080 -
Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index
|
Phase 3 | |
Recruiting |
NCT01389583 -
A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients
|
Phase 2 | |
Recruiting |
NCT00777504 -
Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors
|
Phase 4 | |
Completed |
NCT00764595 -
Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor
|
Phase 2 | |
Completed |
NCT00769782 -
Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor
|
Phase 2 | |
Completed |
NCT00098579 -
Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery
|
Phase 1 | |
Completed |
NCT00005862 -
SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas
|
Phase 2 | |
Completed |
NCT00004895 -
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
|
Phase 2 | |
Recruiting |
NCT02776878 -
A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
|
N/A | |
Completed |
NCT01751919 -
A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)
|
Phase 1 | |
Completed |
NCT01267695 -
Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
|
Phase 2 | |
Terminated |
NCT00956072 -
Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate
|
Phase 3 |